Emergency Management of Severe Hyperkalemia with ECG Changes
In severe hyperkalemia with ECG changes, immediately administer intravenous calcium (10 mL of 10% calcium gluconate or calcium chloride) to stabilize cardiac membranes within 1-3 minutes, followed by combination therapy with IV insulin-glucose (10 units regular insulin with 50 mL dextrose) and nebulized salbutamol (20 mg in 4 mL) to shift potassium intracellularly. 1
Immediate Cardioprotection (0-3 minutes)
IV calcium is your first-line intervention when ECG changes are present or serum potassium ≥6.5 mmol/L 2. This does not lower potassium but reduces membrane excitability in cardiac tissue, preventing life-threatening arrhythmias. The effect is rapid but temporary, buying you time for definitive potassium-lowering therapies.
Potassium Shifting (Within 30-60 minutes)
After cardiac stabilization, deploy combination therapy:
- IV insulin-glucose: 10 units regular insulin with 50 mL dextrose (D50W) - this is the cornerstone of transcellular shifting 1
- Nebulized salbutamol: 20 mg in 4 mL - provides synergistic effect with insulin 1, 2
The combination of nebulized beta-agonists with IV insulin-glucose is more effective than either alone 3, so use both simultaneously in severe cases. The potassium-lowering effect begins within 30-60 minutes 1.
Critical Pitfall: Hypoglycemia Risk
Monitor glucose closely after insulin administration - hypoglycemia risk is particularly high in non-diabetic patients with low baseline glucose 2. Check glucose at 1,2, and 4 hours post-insulin. Beta-agonists have a short duration of effect (2-4 hours), so rebound hyperkalemia can occur 1.
Potassium Elimination
While shifting therapies work, initiate elimination strategies:
- Loop or thiazide diuretics: Use in hypervolemic, non-oliguric patients with residual kidney function 1, 4
- Hemodialysis: Definitive option for refractory cases, oliguric patients, or end-stage renal disease 1, 2
Adjunctive Therapies
Sodium bicarbonate: Limited to patients with severe metabolic acidosis 1, 2. Evidence for its use is equivocal in the absence of acidosis 3.
Avoid sodium polystyrene sulfonate (Kayexalate): No longer recommended due to questionable efficacy and risk of gastrointestinal adverse events including colonic necrosis 2.
Newer Potassium Binders
Sodium zirconium cyclosilicate and patiromer show promise but require further validation in acute emergency settings 2. These are more appropriate for preventing recurrence rather than acute management.
Monitoring Protocol
Continuously monitor:
- ECG changes - watch for resolution of peaked T-waves, widened QRS, or other conduction abnormalities
- Serum potassium trajectory - recheck within 1-2 hours after initial interventions
- Glucose levels - to prevent post-insulin hypoglycemia
- Cardiac rhythm - for arrhythmia development
Post-Stabilization Strategy
After acute correction, focus on preventing recurrence 5. Evaluate reversible causes (acute kidney injury, metabolic acidosis, medications). Do not automatically discontinue renin-angiotensin-aldosterone system inhibitors (RAASi) - discontinuation is associated with higher mortality and major adverse cardiovascular events 1. Instead, consider potassium binders to enable continuation of cardioprotective RAASi therapy 1, 5.
Reassess potassium within 1 week and implement a tailored plan addressing risk factors for recurrence 1, 5.